This test quantifies the prostate cancer gene 3 (PCA3) and PSA RNA levels in post-DRE first-catch urine specimens to aid in the detection of prostate cancer among men aged 50 years or older with elevated serum PSA and history of negative biopsy results [38]. This evidence concerns the gene PCA3 and prostate carcinoma.